Guided Therapeutics (GTHP) Operating Expenses (2010 - 2025)

Guided Therapeutics (GTHP) has 16 years of Operating Expenses data on file, last reported at $1.2 million in Q4 2025.

• For the quarter ending Q4 2025, Operating Expenses rose 119.55% year-over-year to $1.2 million; the trailing twelve-month figure through Dec 2025 stood at $2.9 million (up 39.46% YoY), and the FY2025 full-year result was $2.9 million, up 39.48% from the prior year.
• Operating Expenses rose to $1.2 million in Q4 2025, from $520000.0 in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $1.5 million in Q2 2023 to a low of $363000.0 in Q1 2024.
• A 5-year average of $706850.0 and a median of $591000.0 in 2021 frame the typical range for Operating Expenses.
• Across the five-year window, Operating Expenses surged 240.08% in 2021 and slumped 57.59% in 2024, its largest moves.
• Tracing GTHP's Operating Expenses over 5 years: stood at $476000.0 in 2021, then jumped by 82.56% to $869000.0 in 2022, then slumped by 42.35% to $501000.0 in 2023, then advanced by 6.19% to $532000.0 in 2024, then soared by 119.55% to $1.2 million in 2025.
• Business Quant data shows GTHP's Operating Expenses at $1.2 million in Q4 2025, $520000.0 in Q3 2025, and $842000.0 in Q2 2025.